Equillium, Inc. (EQ)


-0.44 (-14.01%)
Symbol EQ
Price $2.7
Beta 1.343
Volume Avg. 0.03M
Market Cap 107.866M
Shares () -
52 Week Range 1.66-7.12
1y Target Est -
DCF Unlevered EQ DCF ->
DCF Levered EQ LDCF ->
ROE -96.50% Strong Sell
ROA -90.90% Strong Sell
Operating Margin -
Debt / Equity 41.05% Neutral
P/E -
P/B 1.63 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest EQ news

Mr. Bruce Steel
NASDAQ Global Market

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.